Alkermes plc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales
Alkermes plc. (ALKS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales of -$1.14 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales · last filed 2015-02-24
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, sales for the quarter ending 2014-12-31 was $0.00.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, sales for the quarter ending 2014-09-30 was $0.00.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, sales for fiscal 2014 was -$1.14M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $0.00 derived: sum of 2 quarters · filed 2015-02-24 | -$1.14M 10-K · filed 2015-02-24 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$1.14M 10-Q · filed 2014-10-29 | ||
| 2014-06-30 | -$1.14M 10-Q · filed 2014-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |